N. Basset-Seguin

发表

P16INK4A is implicated in both the immediate and adaptative response of human keratinocytes to UVB irradiation

M. Chazal, C. Marionnet, L. Michel, 2002, Oncogene.

Analysis of HPV16 E6 and mutant p53-transfected keratinocytes in reconstituted epidermis suggests that wild-type p53 inhibits cytokeratin 19 expression.

J. Schiller, N. Basset-Seguin, J. Molès, 1994, Journal of cell science.

TP53 tumor suppressor gene and skin carcinogenesis.

N. Basset-Seguin, J. Molès, J. Guilhou, 1994, The Journal of investigative dermatology.

Update of the European guidelines for basal cell carcinoma management

K. Peris, N. Basset-Seguin, C. Ulrich, 2014, European Journal of Dermatology.

Topical methyl aminolevulinate photodynamic therapy for management of basal cell carcinomas in patients with basal cell nevus syndrome improves patient’s satisfaction and reduces the need for surgical procedures

N. Basset-Seguin, C. Pauwels, J. Mazereeuw-Hautier, 2011, Journal of the European Academy of Dermatology and Venereology : JEADV.

[Transgenic mice].

P. Demoly, N. Basset-Seguin, J. Guilhou, 1992, Annales de dermatologie et de venereologie.

PTCH mutations and deletions in patients with typical nevoid basal cell carcinoma syndrome and in patients with a suspected genetic predisposition to basal cell carcinoma: a French study

A. Brice, C. Lebbé, N. Basset-Seguin, 2006, British Journal of Cancer.

Differential expression of a human endogenous retrovirus E transmembrane envelope glycoprotein in normal, psoriatic and atopic dermatitis human skin

N. Basset-Seguin, J. Molès, A. Tesnière, 2004, The British journal of dermatology.

Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin.

P. Petrow, N. Basset-Seguin, S. Faivre, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy of Hedgehog Pathway Inhibitors in Basal Cell Carcinoma

N. Basset-Seguin, F. D. de Sauvage, Hayley J. Sharpe, 2015, Molecular Cancer Therapeutics.

Reconstituted skin in culture: a simple method with optimal differentiation.

N. Basset-Seguin, J. Guilhou, J. Demaille, 1990, Differentiation; research in biological diversity.

Usefulness of the ‘two‐step method’ of digital follow‐up for early‐stage melanoma detection in high‐risk French patients: a retrospective 4‐year study

C. Lebbé, N. Basset-Seguin, N. Madjlessi, 2019, The British journal of dermatology.

Daylight photodynamic therapy with methyl aminolevulinate cream is effective and nearly painless in treating actinic keratoses: a randomised, investigator‐blinded, controlled, phase III study throughout Europe

B. Dréno, N. Basset-Seguin, V. von Felbert, 2015, Journal of the European Academy of Dermatology and Venereology : JEADV.

Efficacy and safety of follow‐up field treatment of actinic keratosis with ingenol mebutate 0·015% gel: a randomized, controlled 12‐month study

C. Garbe, J. Lear, N. Basset-Seguin, 2016, British Journal of Dermatology.

Consensus recommendations for the treatment of basal cell carcinomas in Gorlin syndrome with topical methylaminolaevulinate‐photodynamic therapy

J. Lear, N. Basset-Seguin, R. Bissonnette, 2014, Journal of the European Academy of Dermatology and Venereology : JEADV.

Inactivation of the CDKN2A and the p53 tumour suppressor genes in external genital carcinomas and their precursors

L. Dubertret, N. Basset-Seguin, S. Queillé, 2007, The British journal of dermatology.

European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics: Update 2022.

A. Lallas, I. Zalaudek, A. Hauschild, 2022, European journal of cancer.

Ef fi cacy of Hedgehog Pathway Inhibitors in Basal Cell Carcinoma

N. Basset-Seguin, F. Sauvage, Hayley J. Sharpe, 2015 .

Mechanisms Underpinning Increased Plasma Creatinine Levels in Patients Receiving Vemurafenib for Advanced Melanoma

S. Chevret, C. Lebbé, N. Basset-Seguin, 2016, PloS one.

Occurrence of type 1 and type 2 diabetes in patients treated with immunotherapy (anti-PD-1 and/or anti-CTLA-4) for metastatic melanoma: a retrospective study

C. Lebbé, N. Basset-Seguin, M. Resche-Rigon, 2018, Cancer Immunology, Immunotherapy.

Germline mutations of the INK4a-ARF gene in patients with suspected genetic predisposition to melanoma

H. Cavé, C. Lebbé, N. Basset-Seguin, 2004, British Journal of Cancer.

Divergence between the high rate of p53 mutations in skin carcinomas and the low prevalence of anti-p53 antibodies

R. Lubin, N. Basset-Seguin, F. Galisson, 2001, British Journal of Cancer.

Inhibition of the Proprotein Convertases Represses the Invasiveness of Human Primary Melanoma Cells with Altered p53, CDKN2A and N-Ras Genes

N. Dumaz, N. Basset-Seguin, N. Scamuffa, 2010, PloS one.

A French CDK4-positive melanoma family with a co-inherited EDNRB mutation.

C. Lebbé, N. Basset-Seguin, P. Wolkenstein, 2007, Journal of dermatological science.

Frequency and Genomic Aspects of Intrinsic Resistance to Vismodegib in Locally Advanced Basal Cell Carcinoma

Ismael Padioleau, C. Robert, B. Dréno, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Adherence to topical therapies in actinic keratosis: A literature review

M. Lebwohl, K. Peris, N. Basset-Seguin, 2016, The Journal of dermatological treatment.

Structured Expert Consensus on Actinic Keratosis: Treatment Algorithm Focusing on Daylight PDT

K. Peris, S. Ibbotson, N. Basset-Seguin, 2017, Journal of cutaneous medicine and surgery.

c-fos proto-oncogene expression in bronchial biopsies of asthmatics.

J. Bousquet, P. Demoly, P. Chanez, 1992, American journal of respiratory cell and molecular biology.

Autoimmune diabetes induced by PD-1 inhibitor—retrospective analysis and pathogenesis: a case report and literature review

C. Lebbé, N. Basset-Seguin, J. Gautier, 2017, Cancer Immunology, Immunotherapy.

Characterization of specific leukotriene C4 binding sites on cultured human keratinocytes

L. Dubertret, L. Michel, N. Basset-Seguin, 1988, The British journal of dermatology.

Photodynamic therapy for actinic keratosis in organ transplant patients

J. Lear, N. Basset-Seguin, C. Ulrich, 2013, Journal of the European Academy of Dermatology and Venereology : JEADV.

Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open-label trial.

A. Hauschild, P. Ascierto, R. Dummer, 2017, European journal of cancer.

Germline and somatic mutations of the INK4a-ARF gene in a xeroderma pigmentosum group C patient.

N. Basset-Seguin, A. Sarasin, T. Magnaldo, 2002, The Journal of investigative dermatology.

Defining and recognising locally advanced basal cell carcinoma

J. Grob, B. Dréno, N. Basset-Seguin, 2015, European Journal of Dermatology.

Variants of the MATP/SLC45A2 gene are protective for melanoma in the French population

B. Prum, P. Dieudé, C. Lebbé, 2008, Human mutation.

Melanocortin 1 receptor (MC1R) gene variants may increase the risk of melanoma in France independently of clinical risk factors and UV exposure

C. Lebbé, N. Basset-Seguin, P. Verpillat, 2004, Journal of Medical Genetics.

p53 gene mutations in human epithelial skin cancers.

N. Basset-Seguin, C. Theillet, J. Molès, 1993, Oncogene.

INK4a‐ARF mutations in skin carcinomas from UV irradiated hairless mice

K. Mollier, N. Basset-Seguin, A. Fourtanier, 2004, Molecular carcinogenesis.

Sentinel Lymph Node Biopsy in Cutaneous Squamous Cell Carcinoma Series of 37 Cases and Systematic Review of the Literature.

L. Vercellino, C. Lebbé, N. Basset-Seguin, 2018, Acta dermato-venereologica.

Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial.

A. Hauschild, P. Ascierto, R. Dummer, 2015, The Lancet. Oncology.

Association study of the g.8818A>G polymorphism of the human agouti gene with melanoma risk and pigmentary characteristics in a French population.

C. Lebbé, N. Basset-Seguin, B. Gérard, 2005, Journal of dermatological science.

A Large French Case-Control Study Emphasizes the Role of Rare Mc1R Variants in Melanoma Risk

S. Gazal, N. Dumaz, N. Basset-Seguin, 2014, BioMed research international.

Genetic variation at KIT locus may predispose to melanoma

S. Puig, N. Dumaz, N. Basset-Seguin, 2013, Pigment cell & melanoma research.

Assessment of tyrosinase variants and skin cancer risk in a large cohort of French subjects.

T. Jouary, N. Basset-Seguin, B. Grandchamp, 2011, Journal of dermatological science.

New trends in the susceptibility to melanoma.

N. Basset-Seguin, B. Grandchamp, N. Soufir, 2009, Cancer treatment and research.

The A148T variant of the CDKN2A gene is not associated with melanoma risk in the French and Italian populations.

K. Peris, C. Lebbé, N. Basset-Seguin, 2006, The Journal of investigative dermatology.

Transient pituitary ACTH-dependent Cushing syndrome caused by an immune checkpoint inhibitor combination

Jacques Young, C. Lebbé, N. Basset-Seguin, 2017, Melanoma research.

[Patched/Sonic Hedgehog pathway and basal cell carcinoma].

N. Basset-Seguin, N. Soufir, 2004, Medecine sciences : M/S.

Metastatic basal cell carcinoma: prognosis dependent on anatomic site and spread of disease.

A. Hauschild, D. Schadendorf, R. Dummer, 2014, European journal of cancer.

Prognostic factors and predictive signs of malignancy in adult dermatomyositis. A study of 32 cases.

J. Roujeau, N. Basset-Seguin, R. Gherardi, 1990, Archives of dermatology.

Emerging drugs for the treatment of basal cell carcinoma

N. Basset-Seguin, F. Herms, 2021, Expert opinion on emerging drugs.

Association between INK4a-ARF and p53 mutations in skin carcinomas of xeroderma pigmentosum patients.

L. Dubertret, N. Basset-Seguin, J. Molès, 2000, Journal of the National Cancer Institute.

The incidence of metastatic basal cell carcinoma (mBCC) in Denmark, 1997–2010

Lisa I. Wang, J. Hou, N. Basset-Seguin, 2015, European Journal of Dermatology.

Melanoma susceptibility and progression: Association study between polymorphisms of the chemokine (CCL2) and chemokine receptors (CX3CR1, CCR5).

C. Lebbé, N. Basset-Seguin, P. Wolkenstein, 2007, Journal of dermatological science.

EMMPRIN/CD147 is an independent prognostic biomarker in cutaneous melanoma

C. Lebbé, N. Basset-Seguin, A. Janin, 2016, Experimental dermatology.

A-431 cells and human keratinocytes synthesize and secrete the third component of complement.

N. Basset-Seguin, K. Yancey, S. Caughman, 1990, The Journal of investigative dermatology.

Stabilization of multiple metastatic epithelioid sarcoma under treatment with sunitinib malate

C. Lebbé, N. Basset-Seguin, M. Bagot, 2013, The British journal of dermatology.

Physician perceptions and experience of current treatment in actinic keratosis

M. Lebwohl, K. Peris, N. Basset-Seguin, 2015, Journal of the European Academy of Dermatology and Venereology : JEADV.

Vismodegib in neoadjuvant treatment of locally advanced basal cell carcinoma: First results of a multicenter, open-label, phase 2 trial (VISMONEO study)

A. Duhamel, A. Dupuy, N. Basset-Seguin, 2018, EClinicalMedicine.

Vismodegib resistant mutations are not selected in multifocal relapses of locally advanced basal cell carcinoma after vismodegib discontinuation

N. Dumaz, N. Basset-Seguin, N. Soufir, 2019, Journal of the European Academy of Dermatology and Venereology : JEADV.

Vismodegib: A Review in Advanced Basal Cell Carcinoma

N. Basset-Seguin, J. Frampton, 2018, Drugs.

Sebaceous Carcinomas of the Skin: 24 Cases and a Literature Review.

C. Lebbé, N. Basset-Seguin, M. Bagot, 2017, Acta dermato-venereologica.

P16 UV mutations in human skin epithelial tumors

L. Dubertret, N. Basset-Seguin, J. Molès, 1999, Oncogene.

Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: Final update (30-month) of the pivotal ERIVANCE BCC study.

Christopher J. Miller, D. Schadendorf, A. Gesierich, 2014 .

Management of actinic keratosis: a practical report and treatment algorithm from AKTeamTM expert clinicians

B. Dréno, N. Basset-Seguin, M. Richard, 2014, Journal of the European Academy of Dermatology and Venereology : JEADV.

Defective expression of basement membrane-associated C3d,g in papulonodular basal cell carcinomas.

N. Basset-Seguin, K. Yancey, D. Emanuel, 1989, The Journal of investigative dermatology.

Clinical value of combined determination of plasma L-DOPA/tyrosine ratio, S100B, MIA and LDH in melanoma.

C. Lebbé, P. Morel, L. Dubertret, 2007, European journal of cancer.

Heterogeneity of PD-L1 expression and CD8 tumor-infiltrating lymphocytes among subtypes of cutaneous adnexal carcinomas

C. Lebbé, N. Basset-Seguin, M. Battistella, 2019, Cancer Immunology, Immunotherapy.

Position statement on classification of basal cell carcinomas. Part 1: unsupervised clustering of experts as a way to build an operational classification of advanced basal cell carcinoma based on pattern recognition

I. Zalaudek, J. Malvehy, B. Fertil, 2021, Journal of the European Academy of Dermatology and Venereology : JEADV.

Photodynamic therapy for skin field cancerization: an international consensus. International Society for Photodynamic Therapy in Dermatology

P Calzavara-Pinton, H. Wulf, A. Sidoroff, 2012, Journal of the European Academy of Dermatology and Venereology : JEADV.

The major cicatricial pemphigoid antigen is a 180-kD protein that shows immunologic cross-reactivities with the bullous pemphigoid antigen.

J. Saurat, N. Basset-Seguin, P. Bernard, 1992, The Journal of investigative dermatology.

Erosive lichen planus: dramatic response to thalidomide.

N. Basset-Seguin, J. Guilhou, O. Dereure, 1996, Archives of dermatology.

Chairman of EDF Guideline Commitee

S. Chimenti, A. Finlay, N. Basset-Seguin, 2006 .

Guidelines on the use of photodynamic therapy for nonmelanoma skin cancer: an international consensus. International Society for Photodynamic Therapy in Dermatology, 2005.

Ann-Marie Wennberg, Peter Foley, Rik Roelandts, 2007, Journal of the American Academy of Dermatology.

European Dermatology Forum guidelines on topical photodynamic therapy 2019 Part 2: emerging indications – field cancerization, photorejuvenation and inflammatory/infective dermatoses

S. Karrer, N. Basset-Seguin, C. Ulrich, 2019, Journal of the European Academy of Dermatology and Venereology : JEADV.

C3d,g deposits in inflammatory skin diseases: use of psoriatic skin as a model of cutaneous inflammation.

N. Basset-Seguin, J. Guilhou, V. Mils, 1993, The Journal of investigative dermatology.

Pembrolizumab Monotherapy for Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma: A Single-Arm Phase II Trial (KEYNOTE-629)

J. Schachter, J. Grob, R. Gonzalez, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study

A. Hauschild, D. Schadendorf, A. Gesierich, 2017, BMC Cancer.

Squamous Cell Carcinoma Following Photodynamic Therapy for Cutaneous Bowen's Disease in a Series of 105 Patients.

C. Lebbé, N. Basset-Seguin, M. Bagot, 2016, Acta dermato-venereologica.

MC1R and PTCH gene polymorphism in French patients with basal cell carcinomas.

C. Lebbé, L. Dubertret, N. Basset-Seguin, 2006, The Journal of investigative dermatology.

Guideline on the Treatment of Basal Cell

K. Peris, N. Basset-Seguin, C. Ulrich, 2015 .

Efficacy of sonic hedgehog inhibitors rechallenge, after initial complete response in recurrent advanced basal cell carcinoma: a retrospective study from the CARADERM database

B. Dréno, N. Basset-Seguin, M. Beylot-Barry, 2021, ESMO open.

Update on the Management of Basal Cell Carcinoma

N. Basset-Seguin, F. Herms, 2020, Acta dermato-venereologica.

Follow-Up of Patients With Complete Remission of Locally Advanced Basal Cell Carcinoma After Vismodegib Discontinuation: A Multicenter French Study of 116 Patients.

J. Grob, C. Robert, C. Lebbé, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

J. Schachter, J. Grob, N. Basset-Seguin, 2021, Dermatology and Therapy.

Topical methyl aminolaevulinate photodynamic therapy versus cryotherapy for superficial basal cell carcinoma: a 5 year randomized trial.

Rik Roelandts, Sandeep Varma, Lennart Emtestam, 2008, European journal of dermatology : EJD.

C3d,g is present in normal human epidermal basement membrane.

K. Cehrs, N. Basset-Seguin, K. Yancey, 1988, Journal of immunology.

Metastatic basal cell carcinoma : Prognosis dependent on anatomic site and spread of disease qq

A. Hauschild, D. Schadendorf, R. Dummer, 2014 .

European Dermatology Forum guidelines on topical photodynamic therapy

A. Sidoroff, S. Karrer, N. Basset-Seguin, 2015, European Journal of Dermatology.

Sonidegib and vismodegib in the treatment of patients with locally advanced basal cell carcinoma: a joint expert opinion

A. Hauschild, D. Schadendorf, J. Malvehy, 2020, Journal of the European Academy of Dermatology and Venereology : JEADV.

Characterization and Management of Hedgehog Pathway Inhibitor-Related Adverse Events in Patients With Advanced Basal Cell Carcinoma

A. Hauschild, S. Puig, P. Ascierto, 2016, The oncologist.

French ENT Society (SFORL) guidelines for the management of immunodeficient patients with head and neck cancer of cutaneous origin.

C. Lebbé, N. Basset-Seguin, F. Faure, 2014, European annals of otorhinolaryngology, head and neck diseases.

In vitro induction of basal keratinocyte MY7 antigen expression in cutaneous T-cell lymphoma is associated with response to interferon-alfa therapy.

L. Thill, B. Dréno, N. Basset-Seguin, 1993, Archives of dermatology.

Successful Treatment of Generalized Eruptive Keratoacanthoma of Grzybowski with Acitretin

C. Lebbé, N. Basset-Seguin, M. Bagot, 2019, Dermatology and Therapy.

Interexperimental and Interindividual Variations of DNA Repair Capacities After UV-B and UV-C Irradiations of Human Keratinocytes and Fibroblasts

T. Douki, E. Moustacchi, M. Chazal, 2004, Photochemistry and photobiology.

Allele variations in the OCA2 gene (pink-eyed-dilution locus) are associated with genetic susceptibility to melanoma

F. Clerget-Darpoux, C. Lebbé, N. Basset-Seguin, 2005, European Journal of Human Genetics.

A consensus approach to improving patient adherence and persistence with topical treatment for actinic keratosis

M. Lebwohl, K. Peris, N. Basset-Seguin, 2015, International journal of dermatology.

MC 1 R and PTCH Gene Polymorphism in French Patients with Basal Cell Carcinomas

C. Lebbé, L. Dubertret, N. Basset-Seguin, 2010 .

MC1R, SLC45A2 and TYR genetic variants involved in melanoma susceptibility in southern European populations: results from a meta-analysis.

G. Ribas, K. Peris, A. Lluch, 2012, European journal of cancer.

Ultrasound-guided core needle biopsy of superficial lymph nodes: an alternative to fine-needle aspiration cytology for the diagnosis of lymph node metastasis in cutaneous melanoma

R. Porcher, C. Lebbé, N. Basset-Seguin, 2015, Melanoma research.

High levels of c-fos proto-oncogene expression in normal human adult skin.

N. Basset-Seguin, J. Guilhou, J. Blanchard, 1990, The Journal of investigative dermatology.

C-fos and c-jun proto-oncogene expression is decreased in psoriasis: an in situ quantitative analysis.

N. Basset-Seguin, J. Molès, J. Guilhou, 1991, The Journal of investigative dermatology.

European Dermatology Forum guidelines on topical photodynamic therapy 2019 Part 1: treatment delivery and established indications – actinic keratoses, Bowen's disease and basal cell carcinomas

S. Karrer, N. Basset-Seguin, C. Ulrich, 2019, Journal of the European Academy of Dermatology and Venereology : JEADV.

Switch from p53 to MDM2 as differentiating human keratinocytes lose their proliferative potential and increase in cellular size

J. Piette, J. Dazard, N. Basset-Seguin, 2000, Oncogene.

Genes involved in the WNT and vesicular trafficking pathways are associated with melanoma predisposition

D. Schadendorf, G. Ribas, Rajiv Kumar, 2015, International journal of cancer.

Variants of the xeroderma pigmentosum variant gene (POLH) are associated with melanoma risk.

Mickael Guedj, Nicolas Dupin, Pierre Wolkenstein, 2009, European journal of cancer.

Differential molecular profiling between skin carcinomas reveals four newly reported genes potentially implicated in squamous cell carcinoma development

L. Dubertret, M. Chazal, C. Marionnet, 2003, Oncogene.

[Photodynamic therapy with 5-aminolevulinic acid or placebo for recalcitrant foot and hand warts: randomised double-blind trial].

L. Dubertret, N. Basset-Seguin, P. Combemale, 2001, Annales de dermatologie et de venereologie.

PARKIN Inactivation Links Parkinson's Disease to Melanoma.

L. Thomas, S. Klebe, R. Kumar, 2016, Journal of the National Cancer Institute.

Genomic analysis of smoothened inhibitor resistance in basal cell carcinoma.

C. Rudin, R. Bourgon, Grégoire Pau, 2015, Cancer cell.

Genomic Analysis of Smoo thened Inhibitor Resistance in Basal Cell Carcinoma Graphical

C. Rudin, R. Bourgon, Grégoire Pau, 2015 .

Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial.

A. Hauschild, S. Puig, R. Dummer, 2021, The Lancet. Oncology.

Efficacy and Safety of Sonidegib in Adult Patients with Nevoid Basal Cell Carcinoma Syndrome (Gorlin Syndrome): Results from a Phase 2, Double-Blind, Randomized Trial

A. Hauschild, R. Dummer, J. Lear, 2020, Clinical, cosmetic and investigational dermatology.

Genomic analysis identifies new drivers and progression pathways in skin basal cell carcinoma

S. Antonarakis, S. Nikolaev, V. Zoete, 2016, Nature Genetics.

Recent Advanced in the Treatment of Advanced SCC Tumors

N. Basset-Seguin, E. Maubec, 2022, Cancers.

Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study

A. Hauschild, D. Schadendorf, A. Gesierich, 2017, BMC Cancer.

Stage IV cutaneous squamous cell carcinoma: treatment outcomes in a series of 42 patients

C. Lebbé, N. Basset-Seguin, M. Bagot, 2020, Journal of the European Academy of Dermatology and Venereology : JEADV.

Characterization and subcellular localization of calcium-dependent phospholipid binding proteins (annexins) in normal human skin and reconstituted epidermis.

N. Basset-Seguin, J. Guilhou, F. Martin, 1992, The Journal of investigative dermatology.

Single-center study under a French Temporary Authorization for Use (TAU) protocol for ipilimumab in metastatic melanoma: negative impact of baseline corticosteroids

C. Lebbé, N. Basset-Seguin, L. Biard, 2015, European Journal of Dermatology.

Highly sensitive multivariable assay detection of melanocytic differentiation antigens and angiogenesis biomarkers in sentinel lymph nodes with melanoma micrometastases.

R. Porcher, C. Lebbé, N. Basset-Seguin, 2009, Archives of dermatology.

Phase II Study of Pembrolizumab As First-Line, Single-Drug Therapy for Patients With Unresectable Cutaneous Squamous Cell Carcinomas.

P. Petrow, M. Boubaya, J. Grob, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Penoscrotal Paget's disease.

C. Lebbé, N. Basset-Seguin, J. Dauendorffer, 2021, Annales de dermatologie et de venereologie.

Clinical benefit assessment of vismodegib therapy in patients with advanced basal cell carcinoma.

D. Schadendorf, B. Dréno, N. Basset-Seguin, 2014, The oncologist.

TP53 tumor‐suppressor gene and human carcinogenesis

N. Basset-Seguin, J. Guilhou, V. Mils, 1993, Experimental dermatology.

Truncating mutations of TP53AIP1 gene predispose to cutaneous melanoma

L. Thomas, S. Gazal, C. Lebbé, 2018, Genes, chromosomes & cancer.

A Novel Case of Gorlin Syndrome Mosaicism Involving an SMO Gene Mutation: Clinical, Histological and Molecular Analysis of Basaloid Tumours

S. Nikolaev, N. Basset-Seguin, A. Yurchenko, 2021, Acta dermato-venereologica.

Sonidegib in the Treatment of Locally Advanced Basal Cell Carcinoma: A Retrospective Study

C. Lebbé, N. Basset-Seguin, B. Baroudjian, 2022, Acta dermato-venereologica.

Characterization of patients with advanced basal cell carcinoma progressing while receiving Hedgehog pathway inhibitors

N. Basset-Seguin, M. Beylot-Barry, L. Mortier, 2021, The British journal of dermatology.

Assessment of quality of life using Skindex-16 in patients with advanced basal cell carcinoma treated with vismodegib in the STEVIE study

A. Hauschild, P. Ascierto, R. Dummer, 2018, European Journal of Dermatology.

Melanoma and Cutaneous Malignancies Characterization andManagement of Hedgehog Pathway Inhibitor-Related Adverse Events in Patients With Advanced Basal Cell Carcinoma

A. Hauschild, S. Puig, P. Ascierto, 2016 .

Pembrolizumab as first-line therapy in patients with unresectable cutaneous squamous cell carcinoma (cSCC): Phase 2 results from CARSKIN.

P. Petrow, M. Boubaya, J. Grob, 2019, Journal of Clinical Oncology.

1066P Extended-dose cemiplimab in patients with advanced cutaneous squamous cell carcinoma (CSCC): Primary analysis of phase II results

A. Hauschild, D. Schadendorf, N. Basset-Seguin, 2021, Annals of Oncology.

Follow-up of patients with complete remission of locally advanced basal cell carcinoma treated with vismodegib after treatment discontinuation: A retrospective multicentric French study.

J. Grob, C. Robert, C. Lebbé, 2017 .

Impact of treatment breaks on vismodegib patient outcomes: Exploratory analysis of the STEVIE study.

A. Hauschild, P. Ascierto, R. Dummer, 2015 .

Slow dynamic lymphoscintigraphy is not a reliable predictor of sentinel-node negativity in cutaneous melanoma.

E. Hindié, D. Rubello, E. Banti, 2008, Cancer biotherapy & radiopharmaceuticals.

ISET device: a useful tool to answer some questions about the biologic behavior of melanocytic nevus cells.

N. Basset-Seguin, N. Soufir, V. Descamps, 2010, Archives of dermatology.

Position statement on classification of basal cell carcinomas. Part 2: EADO proposal for new operational staging system adapted to basal cell carcinomas

I. Zalaudek, J. Malvehy, B. Fertil, 2021, Journal of the European Academy of Dermatology and Venereology : JEADV.

Correction to: Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study

A. Hauschild, D. Schadendorf, A. Gesierich, 2019, BMC Cancer.

Real-world approach to actinic keratosis management: practical treatment algorithm for office-based dermatology

Thomas Dirschka, Giovanni Pellacani, Josep Malvehy, 2017, The Journal of dermatological treatment.

European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2022.

A. Lallas, I. Zalaudek, A. Hauschild, 2022, European journal of cancer.

Correction to: Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study

A. Hauschild, D. Schadendorf, A. Gesierich, 2019, BMC Cancer.

Vismodegib (VISMO), a hedgehog pathway inhibitor (HPI), in advanced basal cell carcinoma (aBCC): STEVIE study primary analysis in 1215 patients (pts).

A. Hauschild, P. Ascierto, R. Dummer, 2016 .

Treatment patterns and outcomes for patients with locally advanced basal cell carcinoma before availability of Hedgehog pathway inhibitors: a retrospective chart review

J. Grob, T. Jouary, J. Lear, 2017, European Journal of Dermatology.

3342 Assessment of quality of life using Skindex-16 in patients with advanced basal cell carcinoma (BCC) treated with vismodegib in the STEVIE study

A. Hauschild, P. Ascierto, R. Dummer, 2015 .

Topical photodynamic therapy for superficial and nodular basal cell carcinoma

N. Basset-Seguin, 2010 .

New Vision in Photoprotection and Photorepair

C. Lebbé, N. Basset-Seguin, J. Claudel, 2019, Dermatology and Therapy.

Actinic cheilitis: a systematic review of treatment options

C. Lebbé, N. Basset-Seguin, C. Ulrich, 2020, Journal of the European Academy of Dermatology and Venereology : JEADV.

Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes in Advanced Melanoma Patients

C. Volteau, B. Dréno, N. Basset-Seguin, 2018, Journal of immunology research.

Association between endothelin receptor B nonsynonymous variants and melanoma risk.

C. Lebbé, N. Basset-Seguin, B. Gérard, 2005, Journal of the National Cancer Institute.

Vemurafenib in the French temporary authorization for use metastatic melanoma cohort: a single-centre trial

R. Porcher, C. Lebbé, N. Basset-Seguin, 2014, Melanoma research.

Daylight photodynamic therapy for actinic keratosis: an international consensus

P Calzavara-Pinton, H. Wulf, A. Sidoroff, 2012, Journal of the European Academy of Dermatology and Venereology : JEADV.

Visceral lesions occurring during follow‐up of melanoma patients: a true place for other diagnosis than melanoma metastasis

D. Gossot, C. Lebbé, A. Dupuy, 2012, Journal of the European Academy of Dermatology and Venereology : JEADV.

Human genome meeting 2016

Kumar Kshitij Patel, A. Pang, W. Chung, 2016, Human Genomics.

The proto-oncogene c-fos increases the sensitivity of keratinocytes to apoptosis

J. Piette, N. Basset-Seguin, A. Tesnière, 1997, Oncogene.

Interexperimental and interindividual variations of DNA repair capacities after UV‐B and UV‐C irradiations of human keratinocytes and fibroblasts

T. Douki, E. Moustacchi, M. Chazal, 2004 .

Interactions between ultraviolet light exposure and DNA repair gene polymorphisms may increase melanoma risk

P. Dieudé, C. Lebbé, N. Basset-Seguin, 2009, The British journal of dermatology.

Studies of C3d,g in normal human epidermal basement membrane.

N. Basset-Seguin, K. Yancey, 1990, The Journal of investigative dermatology.

Phorbol Ester Decreases Cytosolic Retinoic Acid Binding Protein (CRABP) Capacity in Normal but not Psoriatic Epidermis

N. Basset-Seguin, J. Guilhou, C. Bonne, 1988, The Journal of dermatology.

A Reliable Method for the Selection of Exploitable Melanoma Archival Paraffin Embedded Tissues for Transcript Biomarker Profiling

C. Lebbé, N. Basset-Seguin, A. Janin, 2012, PloS one.

Management of actinic keratosis at specific body sites in patients at high risk of carcinoma lesions: expert consensus from the AKTeam™ of expert clinicians

B. Dréno, N. Basset-Seguin, M. Richard, 2018, Journal of the European Academy of Dermatology and Venereology : JEADV.

EDNRB gene variants and melanoma risk in two southern European populations

F. Cambien, K. Peris, C. Lebbé, 2011, Clinical and experimental dermatology.

Practical approach to the use of daylight photodynamic therapy with topical methyl aminolevulinate for actinic keratosis: a European consensus

H. Wulf, A. Sidoroff, N. Basset-Seguin, 2015, Journal of the European Academy of Dermatology and Venereology : JEADV.

[Mycosis fungoides following non-Hodgkin's cutaneous B-cell lymphoma].

N. Basset-Seguin, J. Guilhou, O. Dereure, 1993, Annales de dermatologie et de venereologie.

Zinc status in HIV-infected patients: relation to the presence or absence of seborrheic dermatitis.

N. Basset-Seguin, J. Guilhou, B. Guillot, 1998, Journal of the American Academy of Dermatology.

[Eccrine porocarcinoma with Bowenoid changes: a challenging diagnosis of adnexal neoplasm].

C. Lebbé, N. Basset-Seguin, A. Janin, 2014, Annales de pathologie.

Long-Term Outcome of Neoadjuvant Tyrosine Kinase Inhibitors Followed by Complete Surgery in Locally Advanced Dermatofibrosarcoma Protuberans

C. Lebbé, N. Basset-Seguin, M. Resche-Rigon, 2021, Cancers.

Comparative analysis of normal and psoriatic skin both in vivo and in vitro.

N. Basset-Seguin, J. Molès, A. Tesnière, 1994, Differentiation; research in biological diversity.

Human genome meeting 2016

A. Pang, W. Chung, J. Lupski, 2016, Human Genomics.

[Basal cell carcinomas].

N. Basset-Seguin, C. Renaud-Vilmer, 2014, La Revue du praticien.

Pembrolizumab for recurrent/metastatic cutaneous squamous cell carcinoma (cSCC): Efficacy and safety results from the phase II KEYNOTE-629 study

J. Schachter, J. Grob, N. Basset-Seguin, 2019, Annals of Oncology.

Locally Aggressive Trichoblastic Tumours (Low-grade Trichoblastic Carcinomas): Clinicopathological Analysis and Follow-up.

C. Lebbé, N. Basset-Seguin, M. Battistella, 2018, Acta dermato-venereologica.

Clinical response to immune checkpoint inhibition in patients with advanced skin cancers receiving concurrent ruxolitinib therapy for haematological malignancy

C. Lebbé, N. Basset-Seguin, S. Bhatia, 2020, The British journal of dermatology.

Ultrasound-guided core needle biopsy (US-CNB) of superficial lymph nodes: An alternative to fine-needle aspiration cytology (FNAC) for the diagnosis of lymph node metastasis in melanoma.

R. Porcher, C. Lebbé, N. Basset-Seguin, 2014 .

MDM-2 protein is expressed in different layers of normal human skin

J. Piette, V. Maréchal, J. Dazard, 1997, Oncogene.

Eruptive squamous cell carcinomas following an acute skin inflammatory disease: A series of four cases

C. Lebbé, N. Basset-Seguin, S. Mourah, 2022, Journal of the European Academy of Dermatology and Venereology : JEADV.

[The INK4a-ARF locus: role in the genetic predisposition to familial melanoma and in skin carcinogenesis].

N. Basset-Seguin, N. Soufir, 2001, Bulletin du cancer.

Comparative analysis of cellular and tissular expression of c-fos in human keratinocytes: evidence of its role in cell differentiation.

P. Demoly, N. Basset-Seguin, J. Molès, 1994, Oncogene.

p53 Patches are not increased in patients with multiple nonmelanoma skin cancers.

N. Basset-Seguin, A. Janin, N. Soufir, 2001, The Journal of investigative dermatology.

Long-term strategies for management of advanced basal cell carcinoma with hedgehog inhibitors.

A. Hauschild, P. Ascierto, R. Dummer, 2023, Critical reviews in oncology/hematology.

Multiple Painful Cutaneous Nodules—Quiz Case

L. Dubertret, N. Basset-Seguin, I. Moulonguet, 2005 .

Human genome meeting 2016

Kumar Kshitij Patel, Jose Maria Gonzalez-Izarzugaza, A. Pang, 2016, Human Genomics.

[Penile squamous cell carcinoma].

C. Lebbé, N. Basset-Seguin, J. Dauendorffer, 2020, Annales de dermatologie et de venereologie.

Expert Recommendations on Facilitating Personalized Approaches to Long-term Management of Actinic Keratosis: The Personalizing Actinic Keratosis Treatment (PAKT) Project

N. Basset-Seguin, P. Calzavara-Pinton, T. Dirschka, 2023, Acta Dermato-Venereologica.

Vismodegib, a Hedgehog pathway inhibitor (HPI), in advanced basal cell carcinoma (aBCC): STEVIE study interim analysis in 300 patients.

A. Hauschild, P. Ascierto, J. Grob, 2013 .

Focal necrotizing myopathy with ‘dropped-head syndrome’ induced by cobimetinib in metastatic melanoma

L. Vercellino, C. Lebbé, N. Basset-Seguin, 2017, Melanoma research.

Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma (aBCC): 18-month update of the pivotal ERIVANCE BCC study.

D. Schadendorf, A. Gesierich, C. Garbe, 2013 .

PARKIN Inactivation Links Parkinson's Disease to Melanoma.

L. Thomas, S. Klebe, R. Kumar, 2016, Journal of the National Cancer Institute.

Osteopenia and fractures associated with long-term therapy with MEK inhibitors

L. Vercellino, C. Lebbé, N. Basset-Seguin, 2018, Melanoma research.

Highly sensitive multivariable assay detection of melanocytic differentiation antigens and angiogenesis biomarkers in sentinel lymph nodes with melanoma micrometastases.

R. Porcher, C. Lebbé, N. Basset-Seguin, 2009, Archives of dermatology.

Dyskeratosis of the Face: A Quiz.

N. Basset-Seguin, M. Bagot, M. Battistella, 2016, Acta dermato-venereologica.

Treatment of bullous pemphigoid with tetracyclines and topical corticosteroids

N. Basset-Seguin, J. Guilhou, B. Guillot, 1997 .

Association between endothelin receptor B nonsynonymous variants and melanoma risk.

C. Lebbé, N. Basset-Seguin, B. Gérard, 2005, Journal of the National Cancer Institute.

High response rate with extended dosing of cemiplimab in advanced cutaneous squamous cell carcinoma

I. Lowy, N. Basset-Seguin, C. Schmults, 2024, Journal for ImmunoTherapy of Cancer.